SYMPLICITY SPYRAL™ RENAL DENERVATION (RDN) SYSTEM

Clinical evidence

The Symplicity Spyral™ RDN system is backed by multiple sham-controlled trials and the largest real-world registry. The SPYRAL HTN clinical program is the largest renal denervation clinical program, studying more than 4,000 patients worldwide.†,‡,1–3 Read on to understand our extensive clinical evidence and sign up to receive the latest resources.

  

  

  

  

Significant, safe, and sustained blood pressure reductions

The Symplicity™ blood pressure procedure uses the Symplicity Spyral™ RDN system, which is proven to deliver significant, safe, and sustained blood pressure reductions.1–4


Significant

> 9

mmHg

mean reduction in office systolic blood pressure (SBP) in patients on and off medications at primary endpoint follow-up in multiple clinical trials§,1,2

Safe

< 0.4%

major adverse events at composite endpoint, including no new incidence of renal artery stenosis (> 70%) at 1 month.2
(N = 253)

Sustained

18

mmHg

mean reduction in office SBP real-world patients at three years with the Spyral catheter, n = 267§,5

§ Results may very across patients.

Reduced blood pressure in the presence and absence of medication

Multiple randomized, sham-controlled trials show blood pressure reductions in the presence and absence of medication following use of the Symplicity Spyral™ RDN system.1,2

Individual trial designs vary.
Results may vary.

Navy blue and blue gradient bar chart showing the levels of blood pressure in the presence and absence of medication

Read on to learn more about the SPYRAL HTN clinical trial program, including:

  

SPYRAL HTN-OFF MED Trial1

Significant blood pressure reductions in the absence of medication at 3 months

Patient baseline characteristics

RDN

Sham

Age (years)

52

53

Sex (male)

64%

68%

Black Americans (% of study)

22%

19%

Office SBP (mmHg)

162.7 ± 7.8

162.9 ± 7.5

24-hr SBP (mmHg)

151.4 ± 8.1

151.0 ± 7.5

Pivotal, randomized, sham-controlled trial to show safety and efficacy of the Symplicity Spyral™ RDN system in uncontrolled hypertension patients on no antihypertensive medications
(n = 331).

Results may vary.

Navy blue and blue gradient bar chart depicting average systolic blood pressure comparisons from the Spyral OFF-MED trial
  • Blood pressure reductions following Symplicity Spyral™ RDN system were present throughout the day and night.
  • 24-hour ABPM primary endpoint not met due to a biased increase in medications in the sham control arm.

SPYRAL HTN-ON MED Trial2

Significant blood pressure reductions with 20% lower medication burden at 6 months with RDN (2.9 RDN vs. 3.5 sham, p = 0.04)

Patient baseline characteristics

RDN

Sham

Age (years)

55

55

Sex (male)

81%

79%

Black Americans (% of study)

17.0%

19.1%

Office SBP (mmHg)

163.0 ± 7.7

163.1 ± 7.9

24-hr SBP (mmHg)

149.6 ± 7.0

149.3 ± 7.0

Randomized, sham-controlled trial to show long-term efficacy and safety of the Symplicity Spyral™ RDN system in uncontrolled hypertension patients on one to three antihypertensive medications (n = 337).

Results may vary.

Navy blue and blue gradient bar chart showing average systolic blood pressure comparisons from the Spyral ON-MED trial

Blood pressure reductions following Symplicity Spyral™ RDN system were present throughout the day and night.

Global SYMPLICITY Registry (GSR)

Enrolled over 3,000 patients:

  • With uncontrolled hypertension on an average of 4.6 medications.
  • With consistent mean number of medications throughout the follow-up period.
  • Treated with the Symplicity Spyral™ and Flex RDN catheters in real-world experience.

Real-world results3,5

Symplicity™ RF system

Baseline BP 165 ± 25 mmHg

Navy blue and blue gradient bar chart showing blood pressure drops for both the Symplicity Spyral™ and Flex RDN catheters

Symplicity Spyral™ and Flex renal denervation catheters safely reduced blood pressure through 36 months, independent of the number and type of baseline antihypertensive medication classes.3,6

Symplicity Spyral™ RDN system

Baseline BP 164 ± 25 mmHg

Navy blue and blue gradient chart highlighting blood pressure drops for the Symplicity Spyral™ RDN catheter to three years

18 mmHg mean reduction in office SBP at three years with the Symplicity Spyral™ catheter.§,5

p < 0.001 at all timepoints versus baseline PB.
Results may vary.

Our body of evidence continues to grow.

SPYRAL AFFIRM Global Study

Now enrolling the post-approval study at sites across the Unites States.

Read the manuscripts.

View product details.

Learn about Symplicity Spyral™ RDN system’s components and their role in the Symplicity™ blood pressure procedure.

See how renal denervation can help.

Learn more about the turning point in hypertension care and how it can help enhance treatment strategies.

Stay connected.

Sign up for email so we can send relevant information and resources directly to your inbox.

† Includes Symplicity Spyral™ and Flex RDN catheters.

‡ Study follow-up is ongoing. Data does not represent follow-up for all patients.

§ Results may vary across patients.

1. Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444–1451. doi: 10.1016/S0140-6736(20)30554-7.

2. Kandzari D, Townsend R, Kario K, et al. Safety and efficacy of renal denervation in patients taking antihypertensive medications. J Am Coll Cardiol. 2023;82(19):1809–1823. doi: 10.1016/j.jacc.2023.08.045.

3. Mahfoud et al. Outcomes following radiofrequency renal denervation according to antihypertensive medications: subgroup analysis of the Global SYMPLICITY Registry DEFINE. EuroPCR 2023.

4. Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet. 2022;399(10234):1401–1410. doi: 10.1016/S0140-6736(22)00455-X.

5. Medtronic data on file. Global SYMPLICITY Registry clinical data snap. 2023.

6. Mahfoud F, Mancia G, Schmieder RE, et al. Outcomes following radiofrequency renal denervation according to antihypertensive medications: subgroup analysis of the Global SYMPLICITY Registry DEFINE. Hypertension. 2023;80(8):1759–1770. doi: 10.1161/HYPERTENSIONAHA.123.21283.